Navigation Links
Pinnaclife Is Excited to Continue Its Partnership With Leading Dermatological Veterinarians
Date:9/4/2012

CORALVILLE, Iowa, Sept. 4, 2012 /PRNewswire/ -- Pinnaclife, Inc., an Iowa-based science company, is excited to continue its partnership with leading dermatological veterinarians Craig Griffin, DVM, Diplomate ACVD and Wayne Rosenkrantz DVM, Diplomate ACVD on its Animal Health Product Line. Dr. Griffin and Dr. Rosenkrantz oversaw initial case studies of Pinnaclife Animal Health Products, and collaborated with the product's inventor Darlene McCord, PhD, FAPWCA, CSO of McCord Research, Pinnaclife's parent company. "We are very excited about the opportunity to work with this company and evaluate the products further in more controlled studies, but the initial preliminary case studies as well as the in vitro results are very promising and we are looking forward to the future of a highly successful product line," said Dr. Rosenkrantz when asked about the Pinnaclife Animal Health Line. 

(Logo: http://photos.prnewswire.com/prnh/20111107/CG00376LOGO)

The veterinarians will continue their partnership with Pinnaclife by conducting future controlled trials on Pinnaclife Animal Health Products as well as writing a newsletter about veterinary dermatology and collaborating on other Pinnaclife veterinary educational materials and product development. Pinnaclife was honored with a visit from Dr. Griffin at last weekend's CVC conference in Kansas City, Missouri.

About Pinnaclife Animal Health
Pinnaclife Animal Health Line is formulated by Dr. Darlene McCord, inventor of the current #1 selling medical human skin care line in North America, with collaboration and testing support from leading veterinary dermatologists Dr. Griffin and Dr. Rosenkrantz. This short line, available only through prescribing veterinarians, boasts products with specific uses, and also features two deterrent products for cases that require a deterrent for licking and chewing.  Visit

SOURCE Pinnaclife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pinnaclife And Hy-Vee Continue To Promote Health And Nutrition
2. Dr. Darlene McCord To Speak At Gildas Club Of The Quad Cities "Lunch and Learn" Hosted By Pinnaclife, Inc.
3. Ted Pacha Joins Pinnaclife as President of its Healthcare Distribution Division
4. Star Scientific, Inc. Files Second-Quarter Financial Report (Net Sales and Gross Profits Continue to Increase) and Updates Research and Marketing Activities
5. PCMA: Part D Plans and PBMs Continue to Deliver Savings in Medicare
6. PathGroup Unveils a New Look; Continues to Expand Footprint
7. Kibow Biotech Marks Its Continued Growth with Relocation to Larger Facilities
8. Brainlab Continues to Advance Global Treatment Access and Consistency in Cancer Care Centers
9. Medisafe 1 Technologies Corp has of Today Acquired 3,100,000 Shares and Continues to Acquire Shares Under its $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share to Facilitate its On-going Acquisitions Activity Plan
10. Pharma Execs Continue Looking For Growth Opportunities In Spite Of Increasing Regulatory Challenges: KPMG Survey
11. Contract Research Organizations Set to Experience Rapid Growth as Development Costs for New Drugs Continue to Rise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... today announced that its BNC101 IND submission has passed ... Bionomics plans to initiate a Phase 1 clinical trial ... with metastatic pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
(Date:8/31/2015)... ... August 31, 2015 , ... The 2015 New ... patients and family members, medical professionals, and researchers, covering a variety of topics ... is a collaborative effort between the Mesothelioma Applied Research Foundation and ...
(Date:8/31/2015)... ... August 31, 2015 , ... Coast Dental Vista is celebrating ... 11 a.m. to 3 p.m. near Albertsons in the Foothill Center, located at 1279 ... Ofelia Rivera and Dr. Jay Lopp. Call (760) 208-2518 for more details or stop ...
(Date:8/31/2015)... ... September 01, 2015 , ... Neuropsychiatric ... injury with emphasis on transcranial near-infrared laser phototherapy ”. , As corresponding author ... has been largely untreatable - with mostly palliative treatments only - and now ...
(Date:8/31/2015)... ... August 31, 2015 , ... NJ Top Docs Presents, Dr. Michael Betsy! Dr. Betsy ... Ridge, New Jersey, Dr. Michael Betsy graduated from Don Bosco Prep in 1990 and was ... team captain in both sports in his senior year. He was inducted into the ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... makers, diagnostic services, and others—to hold down costs? , In a commentary for ... officer of HealthReveal, presents the concept of “clinical efficacy,” which would bind parties ...
Breaking Medicine News(10 mins):Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 3Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3
... be saved every year, thanks to a simple online calculator ... having ovarian cancer at a much earlier stage. Academics ... a new QCancer algorithm using the UK QResearch database. The ... factors to red flag those most likely to have ovarian ...
... (HealthDay News) --Families hoping to improve their fitness and overall ... TV or computer screen and more time being active together, according ... the following tips to help your family get moving and stay ... Stroll together after a family meal or walk around the mall ...
... The current issue of Medical Acupuncture , a ... how the U.S. military is incorporating medical acupuncture to ... in the war zones and the efforts underway to ... online at http://www.liebertpub.com/acu . "The use of ...
... press release is available in French . ... liver during digestion, has been seriously underestimated. A study published ... kill several types of cancer cells, such as those found ... research team, led by Concordia University, included scientists from McGill ...
... bowel disease (IBD) are increasing with time and in ... study in Gastroenterology , the official journal of ... worldwide epidemiology of inflammatory bowel disease is important for ... Gilaad G. Kaplan, MD, MPH, of the University of ...
... substances in licorice used extensively in Chinese traditional medicine ... and gum disease, the leading causes of tooth loss in ... of Natural Products , they say that these substances could ... gum disease. Stefan Gafner and colleagues explain that ...
Cached Medicine News:Health News:Simple online tool to aid GPs in early ovarian cancer diagnosis 2Health News:Simple online tool to aid GPs in early ovarian cancer diagnosis 3Health News:Cancer-killing compound spares healthy cells 2Health News:IBD emerges as a global disease 2
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
... CSV-1000E contrast sensitivity chart test face is the ... world. This test provides for four (4) rows ... of 8 ft (2.5 meters), these gratings test ... 18 cycles/degree. The CSV-1000E provides a full contrast ...
Medicine Products: